Abstract:Background: Patients with rectal cancer who achieve pathologic complete response (pCR) after neoadjuvant chemoradiotherapy (nCRT) may have a better prognosis and may be eligible for non-operative management. The aim of this research was to identify variables for predicting pCR in rectal cancer patients after nCRT and to define clinical risk factors for poor outcome after pCR to nCRT and radical resection in rectal cancer patients. Methods: A retrospective review was performed using the Surveillance, Epidemiology, and End Results (SEER) database from 2004 to 2013. Non-metastatic rectal cancer patients who received radical resection after neoadjuvant chemoradiotherapy were included in this study. Multivariate analysis of the association between clinicopathological characteristics and pCR was performed, and a logistic regression model was used to identify independent predictors for pCR. A nomogram based on the multivariate logistics regression was built with decision curve analyses to evaluate the clinical usefulness. Results: A total of 6,555 patients were included in this study. The proportion of patients with pCR was 20.5% (n = 1,342). The nomogram based on multivariate logistic regression analysis showed that clinical T4 and N2 stages were the most significant independent clinical predictors for not achieving pCR, followed by mucinous adenocarcinoma and positive pre-treatment serum CEA results. The 3-year overall survival rate was 92.4% for those with pCR and 88.2% for those without pCR. Among all the pCR patients, mucinous adenocarcinoma patients had the worst survival, with a 3-year overall survival rate of 67.5%, whereas patients with common adenocarcinoma had an overall survival rate of 93.8% (P < 0.001). Univariate and multivariate analyses showed that histology and clinical N2 stage were independent risk factors. Conclusion: Mucinous adenocarcinoma, positive pre-treatment serum CEA results, and clinical T4 and N2 stages may impart difficulty for patients to achieve pCR. Mucinous adenocarcinoma and clinical N2 stage might be indicative of a prognostically unfavorable biological tumor profile with a greater propensity for local or distant recurrence and decreased survival.

Risk Factors and Treatment Strategies for Local Recurrence of Locally Advanced Rectal Cancer Treated with Neoadjuvant Chemoradiotherapy Followed by Total Mesorectal Excision

Prognostic factors for local recurrence in patients with rectal cancer submitted to neoadjuvant chemoradiotherapy and total mesorectal excision

Risk factors for local recurrence of rectal cancer after curative surgery: A single-center retrospective study

Clinical outcomes of neoadjuvant chemoradiotherapy followed by total mesorectal excision in locally advanced rectal cancer with mesorectal fascia involvement

Risk Factors for Local Recurrence Following Neoadjuvant Chemoradiotherapy for Rectal Cancers.

Re-evaluation of controversial issues in the treatment of cT3N0-2 rectal cancer: a 10-year cohort analysis using propensity-score matching

Local Recurrence after Laparoscopic Resection of T3 Rectal Cancer Without Preoperative Chemoradiation and a Risk Group Analysis: an Asian Collaborative Study

Identification of locally advanced rectal cancer with low risk of local recurrence.

Predictors and Risk Factors of Pathologic Complete Response Following Neoadjuvant Chemoradiotherapy for Rectal Cancer: A Population-Based Analysis

Challenges and shifting treatment strategies in the surgical treatment of locally advanced rectal cancer

MRI Risk Stratification for Tumor Relapse in Rectal Cancer Achieving Pathological Complete Remission after Neoadjuvant Chemoradiation Therapy and Curative Resection

Short- and long-term outcomes of local excision with adjuvant radiotherapy in high-risk T1 rectal cancer patients

Long-term efficacy of preoperative chemoradiotherapy combined with total mesorectal excision for locally advanced rectal cancer: an analysis of 241 patients

Treatment of Locally Recurrent Rectal Cancer: A Review

Risk factors for local recurrence in patients with clinical stage II/III low rectal cancer: A multicenter retrospective cohort study in Japan

Treatment of Locally Recurrent Rectal Cancer

Tumor Immune Microenvironment Biomarkers for Recurrence Prediction in Locally Advanced Rectal Cancer Patients after Neoadjuvant Chemoradiotherapy

MRI-defined High-Risk Rectal Cancer Patients: Outcome Comparison Between Neoadjuvant Chemoradiotherapy Plus TME and TME Plus Adjuvant Chemotherapy or TME Alone

Intermediate Neoadjuvant Radiotherapy Combined with Total Mesorectal Excision for Locally Advanced Rectal Cancer: Outcomes after a Median Follow-Up of 5 Years.

Clinical outcomes in T4 and/or N2 rectal cancer treated with neoadjuvant chemoradiotherapy; A retrospective study

[Predictive Factors for Locally Recurrent Rectal Cancer after Primary Curative Surgery].